Ppar[gamma] agonist for treatment of progressive supranuclear palsy
一种预防性、对象的技术,应用在神经系统疾病、化合物筛选/测试、药物组合等方向,能够解决药物无法充分减轻症状等问题
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach
[0084] New uses for known compounds that modulate PPARγ have now been discovered. In particular, PPARγ agonists, particularly INT131, have been found to be effective in the treatment of progressive supranuclear palsy.
[0085] Accordingly, in one embodiment, the present invention relates to a method of treating progressive supranuclear palsy or a symptom thereof in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt thereof, Pharmaceutical compositions of prodrugs or isomers.
[0086] Without wishing to be bound by a particular theory, it is believed that INT131 increases PPARγ activation in brain cells (including activation of elements in the PPARγ pathway), increases adiponectin levels, improves energy metabolism in brain cells, and reduces or prevents abnormal Tau protein activation. aggregation, by reducing oxidative stress and neuroinflammation, and thus treating progressiv...
Embodiment 1
[0205] Example 1: INT131 is a potent adiponectin upregulator in patients with reduced adiponectin levels
[0206] method
[0207] A randomized, double-blind, placebo-controlled 24-week study was conducted in which adiponectin levels were measured. The study had a 2-week run-in period, a 24-week double-blind treatment period and a 2-week follow-up period. 367 patients with type 2 diabetes mellitus (TD2), a disease in which patients have reduced adiponectin levels, were randomly assigned to receive 0.5, 1, 2, or 3 milligrams ("mg") of INT131 besylate, 45 mg of pioglitazone or placebo for 24 weeks. To measure adiponectin levels, blood was drawn at weeks 0, 2, 6, 12 and 24.
[0208] The results of the study showed that INT131 at doses of 1, 2 and 3 mg resulted in HbA compared with placebo 1c level was statistically significantly lower. Furthermore, the study showed that INT131 at doses of 2 mg and 3 mg reduced HbA 1c Levels at least consistent with 45 mg of pioglitazone, a...
Embodiment 2
[0220] Example 2: INT131 is a potent upregulator of adiponectin in healthy subjects
[0221] method
[0222] A study was conducted to determine the effect of INT131 on serum adiponectin levels. 30 healthy subjects were randomly selected to receive placebo, 0.1mg INT131, 1mg INT131 or 4mg INT131 daily for 14 days. To measure adiponectin levels, blood was drawn on days 1, 4, 8 and 14.
[0223] result
[0224] From day 1 to day 14, administration of placebo and 0.1 mg INT131 did not significantly change serum adiponectin levels, and further administration of 0.1 mg INT131 resulted in no significant change in adiponectin levels compared to placebo. See figure 1 . However, administration of 1 mg or 4 mg INT131 resulted in significant changes in serum adiponectin levels relative to placebo and from day 1 to day 14. Thus, administration of INT131 is capable of upregulating adiponectin in healthy individuals (ie, subjects without reduced adiponectin levels due to disease or d...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com